Karl Kölbeck

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

Sarah Walters, Camille Maringe, Michel P. Coleman et al. · Thorax · 2013 · 571 citations · Full text

Medicine, Biostatistics, Oncology +17

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne et al. · Annals of Oncology · 2017 · 522 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group

Christer Sederholm, Gunnar Hillerdal, Kristina Lamberg et al. · Journal of Clinical Oncology · 2005 · 215 citations · Full text

Medicine, Oncology, Pharmacology +15

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Martin Schüler, Eng-Huat Tan, Kenneth J. O’Byrne et al. · Journal of Cancer Research and Clinical Oncology · 2019 · 35 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17